Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX-Reference-Cited by-同舟云学术

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX

Published:2021-03-15 Issue:2 Volume:15 Page:315-323
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Choi Young Hoon¹²^ORCID,Lee Sang Hyub¹^ORCID,You Min Su¹^ORCID,Shin Bang Sup¹^ORCID,Paik Woo Hyun¹^ORCID,Ryu Ji Kon¹^ORCID,Kim Yong-Tae¹^ORCID,Kwon Wooil³^ORCID,Jang Jin-Young³^ORCID,Kim Sun-Whe³^ORCID

Affiliation:

1. Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

2. Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

3. Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2021/015/GNL015-02-17.pdf

Reference30 articles.

1. Cancer statistics, 2017

2. Perioperative management of pancreatic cancer

3. Advanced pancreatic carcinoma: current treatment and future challenges